Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis
Thoracic Cancer · 2024-05 · 15 (13) · 1072-1081
DOI: 10.1111/1759-7714.15291 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Thoracic Cancer, online erschienen am 26.03.2024. Verfasst von Yao Zhang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. Hauptthemen laut MEDLINE: Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy, Esophageal Neoplasms, Immunotherapy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neoadjuvant chemoimmunotherapy (NCIT) for locally advanced esophageal squamous cell carcinoma (ESCC) is supported by increasing data, but the sample size is limited, and the findings are not completely consistent. We conducted a real‐world study and a meta‐analysis to evaluate the efficacy and safety of NCIT in locally advanced ESCC.
Methods
We retrospectively assessed the outcomes of patients with locally advanced ESCC who completed NICT and subsequent esophagectomy at our hospital between January 2019 and December 2022, including pathological complete response (pCR) rate, major pathological response (MPR) rate, 1‐, 2‐, and 3‐year overall survival (OS) rates, disease control rate (DCR), objective response rate (ORR), 1‐year recurrence rate, R0 resection rate and adverse events. Moreover, a meta‐analysis of 27 published literatures was also conducted for comparison.
Results
In the analysis, 128 patients were studied, with 25% achieving pCR, 46.1% MPR, and 99.2% R0 resection. The 1‐, 2‐, and 3‐year OS rates were 91.41% (95% CI: 85.15%–95.63%), 75.00% (95% CI: 66.58%–82.23%) and 64.84% (95% CI: 55.91%–73.07%).ORR and DCR were 31.2% (95% CI: 23.31–39.99) and 64.1% (95% CI: 55.15%–72.38%), and the 1‐year recurrence rate was 26.7% (95% CI: 22.5%–38.1%). Treatment‐related events occurred in 96.1% but were acceptable. In a meta‐analysis of 27 studies with 1734 patients, pooled rates for pCR, MPR, ORR, DCR, and R0 resection were 29%, 52%, 71%, 97%, and 98%, respectively, with a 1‐year recurrence rate of 12%.
Conclusion
NCIT is safe and provides potential survival benefits for patients with locally advanced ESCC. However, randomized phase 3 trial data is still needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
- Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
- Department of Thoracic Surgery and State Key Laboratory of Genetic Engineering, Fudan University Shanghai Cancer Center, Shanghai, China.
ORCID-Profile: Yao Zhang, Zhihuang Hu, Jialei Wang
Zitieren
APA
Zhang, Y., Li, H., Yu, B., Sun, S., Hu, Z., Wu, X., Zhang, Y., Li, B., Zhang, Y., Xiang, J., Wang, J., & Yu, H. (2024). Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis. Thoracic Cancer, 15(13), 1072-1081. https://doi.org/10.1111/1759-7714.15291
Vancouver
Zhang Y, Li H, Yu B, Sun S, Hu Z, Wu X, et al. Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis. Thoracic Cancer. 2024;15(13):1072-1081. doi:10.1111/1759-7714.15291
BibTeX
@article{Zhang2024,
author = {Zhang, Yao and Li, Huiting and Yu, Bo and Sun, Si and Hu, Zhihuang and Wu, Xianghua and Zhang, Yang and Li, Bin and Zhang, Yawei and Xiang, Jiaqing and Wang, Jialei and Yu, Hui},
title = {Neoadjuvant chemoimmunotherapy for locally advanced esophageal squamous cell carcinoma: Data from literature review and a real‐world analysis},
journal = {Thoracic Cancer},
year = {2024},
volume = {15},
number = {13},
pages = {1072--1081},
doi = {10.1111/1759-7714.15291}
}
EUVIMED